Hepatic Arterial Infusion With Floxuridine and Systemic Irinotecan After Surgery in Treating Patients With Hepatic (Liver) Metastases From Colorectal Cancer

Inclusion criteria

DISEASE CHARACTERISTICS: * Histologically confirmed metastatic colorectal adenocarcinoma * Primary colorectal adenocarcinoma that has been completely resected (R0 disease) * No evidence of residual, viable tumor by abdominal/pelvic helical CT scan or MRI with IV contrast * Metastatic disease * No more than 9 liver metastases * All lesions completely resected or completely treated by ablation (with or without resection) * All lesions treated by ablation must have been less than 5 cm in size and at least 5 mm away from main/left/right portal vein, common bile duct, and inferior vena cava * All resected lesions must have a negative surgical margin (R0) * Disease progression after prior systemic irinotecan for metastatic disease allowed * No extrahepatic metastases confirmed by chest CT scan except colorectal mesenteric lymph node metastases resected at the time of primary tumor resection * No other prior resection of extrahepatic metastases * Must have the entire liver remnant perfused with a single catheter * Must have a nuclear medicine macro-aggregated albumin flow scan to confirm the area of pump perfusion before study registration PATIENT CHARACTERISTICS: Age * 18 and over Performance status * ECOG 0-2 OR * Zubrod 0-2 Life expectancy * Not specified Hematopoietic * WBC at least 3,000/mm\^3 * Absolute granulocyte count at least 1,500/mm\^3 * Absolute neutrophil count at least 1,500/mm\^3 * Platelet count at least 100,000/mm\^3 Hepatic * Bilirubin no greater than 2 mg/dL * Alkaline phosphatase no greater than 2.0 times upper limit of normal (ULN) * AST and ALT no greater than 2.0 times ULN * No active hepatitis B or C infection * No histological evidence of cirrhosis Renal * Creatinine no greater than 1.5 times ULN * Calcium less than 1.3 times ULN Other * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * Postmenopausal women must be amenorrheic for at least 12 consecutive months to be deemed not fertile * Medically fit to begin chemotherapy between 4 and 8 weeks after surgery * Prior cancer allowed if all of the following criteria are met: * Undergone potentially curative therapy for all prior malignancies * No other malignancy within the past 5 years except the following: * Effectively treated basal cell or squamous cell skin cancer * Carcinoma in situ of the cervix that has been effectively treated by surgery alone * Lobular carcinoma in situ of the ipsilateral or contralateral breast treated by surgery alone * No evidence of recurrence of any prior malignancy * No prior hepatic arterial infusion pump malfunction, malperfusion, or infection PRIOR CONCURRENT THERAPY: Biologic therapy * No concurrent immunologic or biologic therapy Chemotherapy * No prior chemotherapy within 4 weeks before hepatic resection or hepatic ablation (with or without resection) * No prior hepatic arterial infusion with fluorouracil or floxuridine Radiotherapy * No concurrent adjuvant radiotherapy to the pelvis * No other concurrent radiotherapy Other * No other concurrent systemic therapy